Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Access here alternative investment news about Akero Therapeutics Announces $70M In New Financing To Advance Therapeutic Pipeline For Nash, Serious Metabolic Diseases
Venture Capital

Akero Therapeutics Announces $70M In New Financing To Advance Therapeutic Pipeline For Nash, Serious Metabolic Diseases

by vcaonline.com posted 1month ago 142 views
Akero Therapeutics Announces $70 Million in New Financing to Advance Therapeutic Pipeline for NASH, Serious Metabolic Diseases SAN FRANCISCO, December 12, 2018-- Akero Therapeutics, Inc., a biotechnology company developing transformational treatments for non-alcohol steatohepatitis (NASH) and other serious metabolic diseases, today announced the company has closed $70 million in new financing. The Series B round was led by Janus Henderson Investors, with participation from new investors Redmile Group, Boxer Capital of Tavistock Group, Cormorant Asset Management, BVF Partners, Rock Springs Capital, and LifeSci Venture Partners, along with existing investors Apple Tree Partners, Atlas Venture, venBio Partners and Versant Ventures.

In this article